RFA-CA-27-006-Full-Announcement.html

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Cancer Institute (NCI)

Funding Opportunity Title

NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)

Activity Code

UG1 Clinical Research Cooperative Agreements - Single Project

Announcement Type

Reissue of

RFA-CA-18-015

Related Notices

Check for any recent Notices of NIH Policy Changes that may impact application requirements.

Funding Opportunity Number (FON)

RFA-CA-27-006

Companion Funding Opportunity

RFA-CA-27-007

, UG1

Clinical Research Cooperative Agreements - Single Project

RFA-CA-27-008

, UG1

Clinical Research Cooperative Agreements - Single Project

Number of Applications

See Section III. 3. Additional Information on Eligibility.

Assistance Listing Number(s)

93.393, 93.399

Funding Opportunity Purpose

This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human subject research study results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery.

NCORP is a community-based research network that:

NCORP will support the following components that will be individually awarded through the respective Request for Applications (RFAs) indicated below:

NCORP Research Bases will serve as the program's research hubs and are expected to:

Funding Opportunity Goal(s)

To identify cancer risks and risk reduction strategies, to identify factors that cause cancer in humans, and to discover and develop mechanisms for cancer prevention and preventive interventions in humans and to reduce cancer risk, incidence, morbidity, and mortality and enhance quality of life in cancer survivors through an orderly sequence from research on interventions and their impact in defined populations to the broad, systematic application of the research results through dissemination and diffusion strategies.

Key Dates

Posted Date

May 21, 2026

Open Date (Earliest Submission Date)

August 18, 2026

September 18, 2026

September 18, 2026

Not Applicable

July 2027

All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

September 19, 2026

Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide, except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts).

Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

Table of Contents

Part 1. Overview Information Key Dates Part 2. Full Text of Announcement Section I. Notice of Funding Opportunity Description Section II. Award Information Section III. Eligibility Information Section IV. Application and Submission Information Section V. Application Review Information Section VI. Award Administration Information Section VII. Agency Contacts Section VIII. Other Information

Part 2. Full Text of Announcement

Section I. Notice of Funding Opportunity Description

This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human research study results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery.

NCORP will support the following components that will be individually awarded through the respective Request for Applications (RFAs) indicated below:

NCORP Research Bases will serve as the program's research hubs and are expected to:

NCORP Community Sites is a healthcare system, a consortium of healthcare systems, or a consortia of community hospitals and/or oncology practices, public hospitals, and/or health care centers that can enhance the representativeness of participants accrued to cancer control, prevention, treatment and care delivery clinical trials and other human subjects research conducted through NCORP and NCTN.

NCORP Academic Community Sites are a consortium led by an academic center with a network of community hospitals and/or oncology practices, public hospitals, and/ or other healthcare centers that serve a patient population that can enhance the representativeness of participants accrued to cancer control, prevention, treatment and care delivery clinical trials and other human subjects research. The academic medical center should have a robust infrastructure to support the accrual of participants across their affiliate organizations.

Key Definitions for the context of this NOFO:

The terms “Clinical Research” and “Clinical Trials” in this NOFO follow the NIH definitions (https://grants.nih.gov/policy/clinical-trials/glossary-ct.htm#ClinicalResearch).

The terms “Human Subject” and “Human Subjects Research” in this NOFO follow the NIH definitions (https://grants.nih.gov/grants/glossary.htm#HumanSubject) NCI Central Institutional Review Board (Central IRB): is a centralized approach to human subject protection through a process that streamlines local IRB review of selected NCI-sponsored trials for institutions across the country by relying on national experts to ensure trials are reviewed efficiently and with the highest ethical and quality standards (https://www.ncicirb.org/about-cirb/).

Community Site Primary Affiliate: In the context of NCORP community-based structure, a "primary affiliate" refers to a hospital, cancer center, physician practice, or other institution where patients/participants are enrolled on a regular and ongoing basis to the menu of NCI-approved clinical trials and other human subjects research available to the NCORP Community Site or Academic Community Site.

Community Site Sub-Affiliate: In the context of NCORP community-based structure, a "sub-affiliate" refers to a practice or organization that contributes to the overall accrual of a primary affiliate site but is located in a separate geographic location(s), is part of the primary affiliate’s business entity, and is managed by the primary affiliate under the primary Affiliate Site’s Federal Wide Assurance (FWA).

Research Base Member Sites: Members sites affiliated with a given Research Base may include NCORP Community and Academic Community Sites, Main members, affiliates, and Lead Academic Participating sites.

Background The NCORP Research Bases support rigorous studies focused on cancer prevention and screening, cancer symptom management, quality of life studies embedded within treatment trials, and cancer care delivery. The integration of cancer prevention, symptom management, QoL, and cancer care delivery research within NCORP creates a comprehensive framework for improving outcomes across the cancer continuum. This synergy enables NCORP to optimize care delivery, and inform national guidelines through evidence generated in representative populations. By leveraging community partnerships and multidisciplinary expertise, NCORP advances science that is both rigorous and relevant. These efforts not only enhance patient experiences but also strengthen the healthcare system’s capacity to deliver high-quality cancer care nationwide.

Cancer prevention research is a cornerstone of NCORP’s mission because it addresses the root causes of cancer before they manifest clinically. By focusing on strategies such as risk reduction, optimal screening and surveillance, and cancer prevention, NCORP helps reduce cancer incidence. This proactive approach not only saves lives but also alleviates the economic and emotional burden of cancer treatment. NCORP’s community-based model ensures these preventive interventions reach patients where they live, making research findings broadly applicable.

Symptom management research within NCORP is vital because cancer patients often experience multiple distressing symptoms—such as cognitive impairment, neuropathy, pain, fatigue, and nausea—that significantly impair daily functioning and emotional well-being. NCORP trials evaluate interventions to prevent or alleviate these symptoms during and after treatment, improving tolerability and adherence to therapy. This includes examining interventions that enhance these dimensions, from behavioral strategies to mitigate treatment side effects to psychosocial support for patients and caregivers. This work is particularly important in community settings, where access to specialized palliative care may be limited. By including symptom management studies, NCORP ensures that advances in supportive care are integrated into routine oncology practice.

Quality of life (QoL) research is central to NCORP’s vision of patient-centered care. Beyond survival, patients value physical comfort, emotional stability, and social functioning. NCORP’s QoL studies embedded with treatment trials help us understand if the advances made with new therapies are accompanied by improved or worse QoL. These efforts recognize that cancer care extends beyond tumor control—it encompasses holistic well-being. By conducting QoL research in community settings, NCORP ensures findings reflect real-world challenges and solutions, ultimately guiding policies and practices that prioritize patient dignity and resilience.

Cancer care delivery research (CCDR) within NCORP focuses on understanding and improving how cancer care is organized, coordinated, and provided in real-world settings. This research examines factors such as access to care, patient-provider communication, and the implementation of evidence-based practices across representative communities. By embedding CCDR studies into community oncology practices, NCORP identifies barriers and facilitators to optimal care, evaluates innovative models like telehealth and team-based approaches, and informs policy changes that enhance efficiency and quality. Ultimately, CCDR ensures that advances in diagnosis, treatment, and supportive care translate into patient-centered outcomes nationwide.

NCORP has streamlined its scientific and operational processes and expanded its review structure with three NCI Coordinating Center for Clinical Trials (CCCT) dedicated scientific Steering Committees, (Symptom Management & Quality of Life, Cancer Care Delivery, and Cancer Prevention) that provide peer-review for scientific concepts. Access to the Clinical Trials Support Unit (CTSU) allows sites access to all current study materials and the Central Investigational Review Board (CIRB) provides human subjects review, all of which increase efficiency and reduces redundancy. In addition, an infrastructure for cancer care delivery research studies has been built in which both interventional and observational care delivery research studies are being conducted.

Overall Goals of NCORP and Scope of this NOFO The overall goal of NCORP is to bring cancer clinical research studies to individuals in their own communities, thereby generating a broadly applicable evidence base that contributes to improved patient outcomes.

The roles of NCORP Community Sites and Academic Community Sites are to provide access to clinical trials close to where patients live in the community..

The role of NCORP Research Bases is to serve as a main research infrastructure and awardees will be expected to contribute to and focus on the following activities:

Scope of Activities for Research Bases The scope of research activities for the proposed NCORP Research Bases encompasses three major areas delineated below:

Area 1: Cancer Control Research; and/or Area 2: Cancer Prevention Research; and Area 3: Cancer Care Delivery Research.

Research Bases must cover Area 1. Areas 2 and 3 are optional.

Additional details and examples of research appropriate for Areas 1-3 are provided below.

Area 1: Cancer Control Research. Efforts in this area should be aimed to reduce the morbidities associated with cancer and its treatment, as well as improve the quality of life of individuals undergoing cancer treatment or with a history of cancer. Studies can include, but are not limited to:

Area 2: Cancer Prevention Research. Efforts in this area should be aimed at reducing cancer risk, incidence and mortality. Studies can include but are not limited to:

Area 3: Cancer Care Delivery Research. Efforts in this area should seek to improve clinical outcomes and patient well-being by intervening on patient, clinician, and organizational factors that influence care delivery with an emphasis on diagnosis, treatment, survivorship, and end-of-life care. The most desirable studies will be those that undertake one or more of the following:

NCORP Trans-network Interactions All NCORP participants will be expected to work jointly towards the NCORP network goals by using the following general strategies:

Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Cooperative Agreement: A financial assistance mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this NOFO.

Application Types Allowed

New

Renewal - Renewal (but only for the awards supported under RFA-CA-18-015)

The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.

Clinical Trial?

Required: Only accepting applications that propose clinical trial(s).

Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards

The National Cancer Institute intends to commit $74.5 million in FY 2027 for up to seven awards.

Award Budget

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Award Project Period

All applicants should request a 6-year project period.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Nonprofits Other Than Institutions of Higher Education

For-Profit Organizations

Local Governments

Federal Governments

Eligible Agencies of the Federal Government

U.S. Territory or Possession

Other

Independent School Districts

Public Housing Authorities/Indian Housing Authorities

Native American Tribal Organizations (other than Federally recognized tribal governments)

Faith-based or Community-based Organizations

Regional Organizations

Foreign Organizations/Foreign Collaborations

Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.

Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.

Required Registrations

Applicant Organizations Applicant organizations must complete and maintain the following registrations as described in the How to Apply - Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications for additional information System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. Foreign organizations must obtain a NATO Commercial and Government Entity (NCAGE) Code (in lieu of a CAGE code) in order to register in SAM. Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.

Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

All PD(s)/PI(s) must be registered with ORCID. The personal profile associated with the PD(s)/PI(s) eRA Commons account must be linked to a valid ORCID ID. For more information on linking an ORCID ID to an eRA Commons personal profile see the ORCID topic in our eRA Commons online help.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply - Application Guide.

2. Cost Sharing This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement NIH Grants Policy Statement Section 1.2 Definition of Terms.

3. Additional Information on Eligibility Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

Section IV. Application and Submission Information

1. Requesting an Application Package The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise (in this NOFO, in a policy notice, or other notice from NIH Guide for Grants and Contracts). Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Page Limitations All page limitations described in the How to Apply – Application Guide and the Table of Page Limits must be followed.

Instructions for Application Submission

The following section supplements the instructions found in the How to Apply – Application Guide and should be used for preparing an application to this NOFO.

SF424(R&R) Cover All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations

SF424(R&R) Other Project Information

Facilities & Other Resources: In addition to standard items for this attachment, the applicants should provide the following information/documentation.

Summary of Collective Bodies/Committees for Research Base Core Functions (use filename: 1-Core Functions).

For a new application, do not contact or name potential members in the application. For a renewal application provide the names only of current members of the established committees in the application. Provide information on committee memberships held by key investigators that will contribute to the core functions of the proposed Research Base. Memberships may include committees such as Executive and Oversight Committees (all members should be listed); Data Safety and Monitoring Board (all members should be listed); Scientific Committees (list only Chair and Vice-Chair positions - do not include subcommittee heads); Community investigators for each Scientific Committee should be listed; and Administrative Committees (list only Chair and Vice-Chair positions - do not include subcommittee heads). Please Note: A table can be used to show this information with column headings for the Staffing Category for the Research Base (i.e., type of committee), Member status (i.e., Chair, Vice-Chair, Member) general category of Research Base or Network Group/NCI Steering Committee/NCI Initiative, specific category or activity; Member Name, Member Title, Member Institution, and Length of Service in the Position. The date the table was prepared should be provided as a sub-heading (e.g., Information Current as of MM, DD, YY).

Constitution and By-Laws for Site & Investigator Membership in the proposed Research Base (use filename: 2-Membership Constitution By-Laws).

Provide a summary of the Constitution & By-Laws for the proposed Research Base related to both site and investigator membership to illustrate how both sites and investigators are recruited and evaluated.

Performance Site Locations including NCORP Sites (use filename: 3-Member sites) List all performance sites that conduct clinical trials and human subjects studies Other Attachments: Applicants must provide the following additional material specified below. Each attachment should be uploaded as a separate PDF using the indicated filenames (which will serve as application bookmarks).Attachment number continues from the previous section.

Attachment 1. Summary of Important Primary Scientific Achievements (use filename: 4-Primary Achievements)

Attachment 2: Summary of Other Important Achievements (use filename: 5-Other Achievements).

Attachment 3: Summary Accrual for All Clinical Trials and Related Studies by CCP&CCDR Category of the Research Base to Research Base Trials(use filename: 6-Member Accruals).

Attachment 4: Conflict of Interest Policy (use filename: 7-COI).

Provide documentation of the Conflict of Interest Policy used by the proposed Research Base to ensure that staff and investigators working on the design, monitoring, and analysis of specific studies do not have any conflicts of interest with respect to the studies. Include policies to maintain study blinding.

Attachment 5: Model Statistical Analysis Template (use filename: 8-Statistical Template).

Provide documentation/example of the proposed Research Base’s standard template used for generating statistical analysis plans for clinical studies as well as the proposed Research Base’s standard "Report of Studies" template for providing information related to ongoing and recently closed studies to its members.

Attachment 6: Audit Policy and On-Site Auditing Summary (use filename: 9-Audit Policy and Auditing Summary).

Attachment 7: Operational Timelines for Development of Clinical Trials and Related Studies (use filename: 10-Study Timelines).

Attachment 8: Data Management and Monitoring Policies & Procedures for Clinical Studies (use filename: 11-Data Management and Monitoring).

Provide documentation of key procedures for data management and monitoring policies for clinical studies, including risk-based central monitoring.

Attachment 9: Key Procedures to Ensure Security and Confidentiality of Patient Data (use filename: 12-Securing Patient Confidentiality).

Provide documentation of key procedures for ensuring the security and confidentiality of patient data, including protected health information.

Attachment 10: Summary Accrual for All Clinical Trials and Related Studies by CCP&CCDR Category of the Research Base to Other Research Base Trials(use filename: 13-Cross Network Member Accruals).

For Renewal applications: Provide documentation of patient accrual on NCORP clinical studies during the current funding period to trials sponsored by other network research bases. Accrual figures should include the unique number of patients enrolled on each NCORP study. Separate accrual numbers should be reported for quality of life accruals. Include the following information: major CPC&CCDR categories (cancer control, prevention, care delivery) all clinical trial phases, as well as longitudinal/cohort/descriptive studies and total column summing accrual across study designs. The timeframe for the period of accrual should be provided as a sub-heading for each table.

SF424(R&R) Senior/Key Person Profile

R&R Budget

Budget forms appropriate for the specific component should be included in the application package. Restricted budgets should be included for Study specific budget (if applicable), CCDR (if applicable), Auditing costs, per-case management not managed through a study budget, Biospecimen core (Cancer Center applicants only).

a) PD/PI Effort Commitment. The minimal effort commitment for the Contact PD/PI must be 1.2 person-months per year. The effort commitment for the other PDs/PIs (if multiple) must be a minimum of 1.2 person-months per year. These effort commitments cannot be reduced in later years of the award. A minimal effort level of 1.2 person-months is required for each PD/PI regardless of whether that individual is designated as contact PD/PI or not. (This commitment cannot be reduced below that level during the projects period).

b) Travel Expenses. Applicants must budget travel funds for four persons (two PDs/PIs or one PD/PI and additional senior investigators and two operations staff members) to attend one NCORP Annual Meeting in-person meeting per year in addition to other travel expenses.

c) Other Expenses. Applicants must include in the budget appropriate expenses to cover development and conduct of trials and human subjects studies across each included scientific area as well as support for the Data Safety Monitoring Board activities and auditing activities. Biobanking costs can be included for Cancer Center applicants.

d) General determination of level of "per-case management" funding (aka capitation funding) for Member Sites other than NCORP Sites. The NCORP provides general total cost support for different types of accrual for member sites depending on the accrual type category. Total cost funding for "per case management" for treatment intervention trials is expected to be provided in following estimated amounts by accrual category per enrolled patient listed below:

Please Note: "Per-case management" funding may be provided out of the Research Base capitation budget for collections of radiologic images (not costs of the actual imaging) but only for NCI/NCORP approved integral and/or integrated imaging studies embedded in NCORP trials and the collection must be coordinated through the Network Radiotherapy and Imaging Core Services Center. Quality assurance/control for significant radiotherapy interventions in NCORP trials is performed by the Network Radiotherapy and Imaging Core Services Centers. "Per-case management" funding may be provided for biospecimens collected for NCI/NCORP approved integral and/or integrated studies in embedded NCTN trials as well as for optional biospecimen collections for future unspecified research if approved by NCI/NCORP.

To justify the budget, the applicant needs to describe using an "Accrual InputTable or Narrative" in the budget narrative detailing the number of patients expected to be accrued in the "screen only" category for intervention trials, intervention category for trials, cohort study or centralized intervention category, and 1 patient biospecimen collection for each enrollment by category site type. The applicant should use the prior funding period as a guide for reasonable estimates of future patient enrollments by accrual type with appropriate justification for any significant changes in anticipated levels of patient enrollments. Cross research base accruals should also be estimated.

The following costs are not supported under this NOFO;

R&R Subaward Budget

PHS 398 Cover Page Supplement

PHS 398 Research Plan All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Specific Aims: Describe the overall Specific Aims for the proposed Research Base addressing the development and conduct of cancer prevention, control, and care delivery (CPC&CCD) trials and human subjects studies in the applicable areas. The study design, methods, and/or interventions for these areas of research may not by themselves be innovative but address important questions or unmet needs. Explain how the completion of these Aims is expected to advance oncology care and enhance cancer care and outcomes through a solutions-oriented approach.

Research Strategy: Organize the Research Strategy section with sub-sections in the specified order and follow the instructions provided below. Start each subsection with the appropriate subsection heading.

Overview Outline the overall strategy and approaches that the applicant team will use to develop and implement its research agenda.

Progress Report for Renewal applicants:

For New applicants:

Provide the highlights of major contributions to cancer-related clinical research, including NCI-supported clinical trials through the venues in which the applicant organization has had access over the last 5 years.

Subsection A. Organizational Leadership, Structure and Operational Management - Address the following areas:

Administrative Leadership